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Abstract: An expedited synthesis of endo-hydroxamic acid aminocarboxylic acid (endo-HXA) com-
pounds has been developed. These monomeric ligands are relevant to the synthesis of metal–macrocycle
complexes using metal-templated synthesis (MTS), and the downstream production of apomacrocycles.
Macrocycles can display useful drug properties and be used as ligands for radiometals in medical imaging
applications, which supports methodological advances in accessing this class of molecule. Six endo-HXA
ligands were prepared that contained methylene groups, ether atoms, or thioether atoms in different
regions of the monomer (1–6). MTS using a 1:2 Fe(III)/ligand ratio furnished six dimeric hydroxamic
acid macrocycles complexed with Fe(III) (1a–6a). The corresponding apomacrocycles (1b–6b) were pro-
duced upon treatment with diethylenetriaminepentaacetic acid (DTPA). Constitutional isomers of the
apomacrocycles that contained one ether oxygen atom in the diamine-containing (2b) or dicarboxylic
acid-containing (3b) region were well resolved by reverse-phase high-performance liquid chromatography
(RP-HPLC). Density functional theory calculations were used to compute the structures and solvated
molecular properties of 1b–6b and showed that the orientation of the amide bonds relative to the pseudo-
C2 axis was close to parallel in 1b, 2b, and 4b–6b but tended toward perpendicular in 3b. This confor-
mational constraint in 3b reduced the polarity compared with 2b, consistent with the experimental trend
in polarity observed using RP-HPLC. The improved synthesis of endo-HXA ligands allows expanded
structural diversity in MTS-derived macrocycles and the ability to modulate macrocycle properties.
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An expedited synthesis of endo-hydroxamic acid amino carboxylic acid (endo-HXA) 
compounds has been developed. These monomeric ligands are relevant to the synthesis of 
metal-macrocycle complexes using metal-templated synthesis (MTS), and the downstream 
production of apo-macrocycles. Macrocycles can display useful drug properties and be used 
as ligands for radiometals in medical imaging applications, which supports methodological 
advances in accessing this class of molecule. Six endo-HXA ligands were prepared that 
contained methylene groups, ether atoms or thioether atoms in different regions of the 
monomer (1–6). MTS using a 1:2 Fe(III):ligand ratio furnished six dimeric hydroxamic acid 
macrocycles complexed with Fe(III) (1a–6a). The corresponding apo-macrocycles (1b–6b) 
were produced upon treatment with diethylenetriaminepentaacetic acid (DTPA). 
Constitutional isomers of the apo-macrocycles that contained one ether oxygen atom in the 
diamine- (2b) or the dicarboxylic acid- (3b) containing region were well resolved by reverse-
phase liquid chromatography. Density functional theory (DFT) calculations used to compute 
the structures and solvated molecular properties of 1b–6b, showed the orientation of the 
amide bonds relative to the pseudo C2 axis was close to parallel in 1b, 2b, and 4b–6b, but 
tended towards perpendicular in 3b. This conformation constraint manifest in 3b reduced the 
polarity compared with 2b, and was consistent with the experimental trend in polarity 
observed using RP-HPLC. The improved synthesis of endo-HXA ligands allows expanded 






Almost all bacteria produce low-molecular-weight organic ligands known as siderophores 
that have high affinity toward Fe(III).1-4 The formation of Fe(III)-siderophore complexes 
occurs as the first step in siderophore-mediated bacterial iron acquisition, which serves to 
increase the availability of insoluble Fe(III) to bacteria, as essential for survival.5-8 Due to 
evolutionary pressure, a vast array of siderophores are produced with different molecular 
structures.4 A large sub-set of siderophores contain the hydroxamic acid functional group as 
the Fe(III) binding motif. Trimeric hydroxamic acid siderophores form hexadentate 1:1 
complexes with Fe(III) and include linear desferrioxamine B (DFOB) and macrocyclic 
desferrioxamine E (DFOE).9-11 Dimeric hydroxamic acid macrocyclic siderophores isolated 
from nature include putrebactin, avaroferrin, bisucaberin and alcaligin (Chart 1). These 
tetradentate macrocycles form 2:3 Fe(III):ligand complexes at pH 7 and 1:1 complexes at 
acidic pH values,12-19 and can form complexes with other metal ions, including V(V), Mo(VI) 
and Cr(V).16,20,21 Bisucaberin has been shown to have anti-cancer potential through Fe(III) 
deprivation mechanisms,17 which provides impetus to exploring methods beyond total 
synthesis22 to improve access to these types of molecules and to allow increased structural 
diversity. This is in accord with the broader potential of macrocycles as useful drug leads and 
inhibitors of protein-protein interactions,23-28 which underpins developments in macrocycle 
synthesis. 
 Metal-templated synthesis (MTS) from endo-hydroxamic acid amino carboxylic acid 
(endo-HXA) monomers has been used to furnish a range of dimeric,29 trimeric,30,31 or 
tetrameric32 hydroxamic acid macrocycles. In a different approach, trimeric macrocyclic 
hydroxamic acid siderophores have been produced using Fe(III)-mediated macrolactonization 
of a pre-assembled linear trimer.33 Trimeric DFOE was first produced using MTS as a 
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supramolecular chemistry approach from a 1:3 complex formed in situ between Fe(III) and 
the endo-HXA monomer 4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoic acid (PBH).30 
The flanking amino and carboxylic acid groups of contiguous PBH ligands were favourably 
positioned around the Fe(III) template for ring closure using diphenylphosphoryl azide 
(DPPA)-mediated peptide coupling. Ring-expanded analogues of trimeric DFOE were 
subsequently generated using MTS with the replacement of PBH with endo-HXA monomers 
that contained additional methylene groups in the diamine- or carboxylic acid-containing 
region of the ligand.31 In a given MTS system, the nature of the metal ion template, the endo-
HXA and the reaction stoichiometry can direct the architecture of the terminal macrocycle. 
The use of Zr(IV) (typical coordination numbers in the range 6–8)34,35 and the endo-HXA 5-
[(5-aminopentyl)(hydroxy)amino]-5-oxopentanoic acid (PPH) in a 1:4 ratio furnished a 
tetrameric hydroxamic acid macrocycle that saturated the Zr(IV) octadentate coordination 
sphere.32 A selection of natural product dimeric hydroxamic acid macrocycles has been 
generated by MTS using a 1:2 Fe(III):ligand reaction stoichiometry.29 
 
 
Chart 1. Dimeric hydroxamic acid macrocyclic siderophores characterized from nature. 
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One shortcoming of MTS in generating new macrocycles is the availability of the endo-HXA 
monomers. The existing literature syntheses36,37 provide monomers in modest yields (about 
10 mg per 5-day synthetic undertaking), which can hinder progress in exploring subsequent 
MTS chemistry. Our interest in increasing the traction of MTS for producing macrocycles 
tailored towards a given metal ion prompted us to re-examine the synthesis of endo-HXA 
monomers. In this work, we describe an expedited synthesis of endo-HXA monomers that 
gives significantly greater yields of product and uses a class of starting reagent that allows an 
expansion in structural diversity. The library of new endo-HXA monomers described here 
has been used in an MTS approach to generate a set of structurally diverse dimeric 
hydroxamic acid macrocycles, which have been characterized as holo-(Fe(III)-loaded) 
complexes and apo-(Fe(III)-free) ligands. These results provide the potential to expand MTS 
to generate new macrocycles with structures that deviate beyond those of natural products. 
 
Results and discussion 
 
Synthesis of endo-hydroxamic acid amino carboxylic acid (endo-HXA) monomers 
The first described synthesis of PBH undertook a reaction between O-benzyl-N-(4-
cyanobutyl)hydroxylamine and succinic anhydride followed by nitrile-to-amine reduction 
(Raney Ni), and O-benzyl deprotection (H2 over Pd/C).36,38,39 The reaction conditions were 
harsh, and furnished PBH in an overall yield of 17% (Scheme 1a). A subsequent synthetic 
scheme used milder conditions37 and has been widely adopted by others,29,31,32,40 although the 
route is time intensive and low yielding (Scheme 1b). 
 The current work began by considering improvements to the synthetic efficiency of 
endo-HXA monomers. Modifications aimed to improve the synthetic route at the level of 
yield, reaction times and/or safety, and are discussed with reference to PBH. First, the more 
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commonly used starting reagent in the more recent method (Scheme 1b) 1,5-dibromopentane 
or 1-bromo-5-chloropentane was replaced with 1-amino-5-pentanol (Scheme 2). The initial 
stage of the installation of the hydroxamic acid group involved the reaction between N-Boc-
1-amino-5-pentanol and either O-tert-butyl-N-(2-nitrophenylsulfonyl)hydroxylamine or O-
benzyl-N-(2-nitrophenylsulfonyl)hydroxylamine under Mitsunobu conditions. The N,O-bis-
protected hydroxylamine reagents have been prepared in previous work41 and used in the 
synthesis of hydroxamic acid-based compounds, including DFOB.42 The NH group in these 
reagents is sufficiently acidic (pKa 5.1) for use in the Mitsunobu reaction. The 2-
nitrophenylsulfonyl (nosyl) N-protecting group was selected since it could be removed under 
mild conditions with a thiolate in an orthogonal fashion to the O-(tert-butyl)-N-alkyl-
hydroxylamine (Scheme 2, PG1) and the O-benzyl-N-alkyl-hydroxylamine (Scheme 2, PG2) 
protecting group systems. The nosyl protecting group has been used in the synthesis of linear 
hydroxamic acids and to prepare other type of ligands for radiochemistry.41-43 Following the 
reaction with succinic anhydride to complete the installation of the hydroxamic acid group, 
PBH could be generated from the O-tert-butyl-protected intermediate upon global 
deprotection with trifluoroacetic acid (TFA), or from the O-benzyl-protected intermediate 
with removal of the N-Boc group with dilute TFA followed by hydrogenation over Pd/C. The 
intermediates were readily purified using auto flash chromatography with the purity 
increasing from 13–16 (80%) to 17–22 (95%) to 1–6 (95%). The purity of 1–6 was sufficient 




Scheme 1. Previous syntheses of the archetypal endo-HXA 4-[(5-
aminopentyl)(hydroxy)amino]-4-oxobutanoic acid (PBH) via route (a)36,38,39 or (b).37 
Conditions (a): (i) thiazolidine-2-thione, CH2Cl2, Et3N, 2-chloro-1-methylpyridinium iodide, 
r.t., 24 h, yield not specified (ii) diisobutylaluminium hydride, toluene, –78 °C, 2 h, then –40 
°C, 3 h, 61%, (iii) BnO-NH3Cl, H2O, MeOH, KOH, 1 h, 0 °C, then NaBH3CN, HCl in 
MeOH, 3 h, 84%, (iv) succinic anhydride, pyridine, 100 °C for 1.5 h, then r.t. overnight, 
98%; (v) H2/Raney Ni/NH3/CH3OH, 0 °C, 3 h, 90%, (vi) H2, 10% Pd/C, CH3OH, HCl, 3 h, 
23%; (b): (i) potassium phthalimide, DMF, 20 h, 84%, (ii) BnO-NH-Boc, NaH, NaI, DMF, 
19 h, 85 °C, 82%, (iii) NH2NH2, EtOH, 3 h, 90 °C; CbzCl, H2O, 1,4-dioxane, 0–20 °C, 12 h, 
85% (2 steps) (iv) 20% TFA, 2 h, 20 °C, 76%, (v) succinic anhydride, pyridine, 100 °C, 2 h, 
then 20 °C for 12 h, 72%, (vi) H2, 10% Pd/C, tBuOH, 1,4-dioxane, HCl, 3 h, 100%. 
 
The new synthetic path developed here provided an improvement in overall yield and 
time-efficiency, compared to earlier methods. The overall yield (Scheme 2) was 49% and the 
overall reaction time for 5 (PG1) or 6 (PG2) steps was about 24 h. This compared to an overall 
yield of 10% and 65 h (6 steps) for the earliest devised synthesis (Scheme 1a),36,38,39 or 32% 
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and 75 h (7 steps) for the more recent synthesis (Scheme 1b).37 In addition to gains in 
synthetic efficiency, the new route allowed for expanded structural diversity, due to the 
availability of different types of amino-alcohol start reagents and gave more flexibility, due to 
the orthogonality of the N-protecting groups. 
This work focused on PPH as the primary endo-HXA monomer, which has been used 
successfully in previous MTS approaches. PPH contains an additional methylene group in the 
dicarboxylic acid-containing region than PBH and is prepared by replacing succinic 
anhydride with glutaric anhydride (PPH, 1). The replacement of 1-amino-5-pentanol with 2-
(2-aminoethoxy)ethanol gave a PPH analogue with an ether oxygen atom in the diamine-
containing region (PPHNO, 2). A thioether atom could be introduced in the diamine-
containing region using 2-((2-aminoethyl)thio)ethanol as the start reagent, although this was 
not pursued here, to maintain a reasonable scope of workload. The replacement of glutaric 
anhydride with 1,4-dioxane-2,6-dione or 1,4-oxathiane-2,6-dione, gave PPH analogues 
containing an ether (PPHCO, 3) or thioether (PPHCS, 5) atom in the dicarboxylic acid-
containing region. Replacements in both the diamine- and the dicarboxylic acid-containing 
regions gave endo-HXA ligands containing variable substitutions of ether and thioether 




Scheme 2. Improved synthesis of endo-HXA monomers 1–6. Conditions: (i) Boc2O, Et3N, 
DCM, r.t., 4 h, (ii) tBuO-NH-Ns (n = 1) or BnO-NH-Ns (n = 2), Ph3P, DIAD, THF, 40 °C, 8 
h, (iii) 2-mercaptoethanol, DBU, DMF, r.t., 3 h, (iv) glutaric anhydride (1, 2), 1,4-dioxane-
2,6-dione (3, 4), or 1,4-oxathiane-2,6-dione (5, 6), DCM, r.t., 3 h (v) TFA:DCM 9:1, r.t., 4 h 
(n = 1), or TFA:DCM 1:9, r.t., 2 h; H2, 10% Pd/C, tBuOH, 60 °C, 0.5 h (two steps) (n = 2). 
PG1 was used for 1, 2, 5 and 6. PG2 was used for 3 and 4. 
 
 A further improvement was gained in the reaction step with the anhydride (Scheme 2, 
step (iv)) by replacing pyridine with dichloromethane and triethylamine. The triethylamine 
base was subsequently determined to be unnecessary. These modifications mitigated the high 
variability in yields (40–80%) and reduced the reaction time for this step from 24 h to 3 h. 
Use of the O-tert-butyl protecting group for the hydroxamic acid was first pursued as a 
general method for endo-HXA ligands, since this could potentially enable global deprotection 
of the N–OtBu group and the NH–Boc group with high concentrations of TFA. However, 
similar to observation from others,42 in some instances the high concentration of TFA 
promoted the hydrolysis of the hydroxamic acid group. This reactivity was dependent upon 
the nature of the anhydride employed in the reaction. The N–OtBu protecting group strategy 
was incompatible with 1,4-dioxane-2,6-dione, but was compatible with glutaric anhydride 
and 1,4-oxathiane-2,6-dione. This was fortuitous in the case of 1,4-oxathiane-2,6-dione, since 
this mitigated issues with sulfur poisoning the catalyst in the Pd/C reductive deprotection 
route. The 1,4-dioxane-2,6-dione system required the use of a N–OBn protecting group, 
necessitating a two-step deprotection procedure (Scheme 2, step (v)). The instability of ether-
containing molecules towards N–OtBu deprotection has been reported.42 All endo-HXA 
ligands 1–6 were characterised using 1H and 13C and 1H-1H COSY NMR spectroscopy and 
HRMS (Fig. S1–S6). 
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Synthesis of Fe(III)-loaded dimeric hydroxamic acid macrocycles 1a–6a using MTS 
The set of endo-HXA monomers 1–6 allowed an examination of the synthesis of new 
hydroxamic acid macrocycles using MTS. MTS relies on the formation of a metal-ligand 
supramolecular assembly in which the terminal amine and carboxylic acid groups of 
contiguous endo-hydroxamic acid amino carboxylic acid monomers are suitably positioned to 
allow ring closure upon in situ peptide coupling. This is designed to provide facile access to 
metal-loaded macrocycles (holo-macrocycles), with apo-macrocycles accessible upon 
incubation with a high concentration of chelator to compete for the templating metal ion 
(Scheme 3). The MTS reaction was conducted using a 1:2 Fe(III):ligand stoichiometry, with 
in situ amide-bond forming chemistry undertaken with DPPA and triethylamine. 
 
 
Scheme 3. Synthesis of dimeric hydroxamic acid macrocycles as Fe(III) complexes (holo-
macrocycles: 1a–6a) or as free ligands (apo-macrocycles: 1b–6b). 
 
The MTS reaction solution was analysed using LC-MS, with selected ion monitoring (SIM) 
as the detection mode. The 1:2 Fe(III):ligand stoichiometry was selected to promote the 
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generation of dimeric macrocycles (Table 1). It was possible that the MTS system might 
generate trimeric macrocycles, since this configuration would stabilise the octahedral 
coordination preference of Fe(III). The SIM values selected for the analysis correlated with 
the intrinsically charged Fe(III)-dimeric macrocycle ([M]+) and the protonated adduct 
([M+H]+) of the neutral Fe(III)-trimeric macrocycle. 
 
Table 1 HPLC retention times for holo-macrocycles 1a–6a and apo-macrocycles 1b–6b 
Holo-macrocycle  tR 
(min) 
m/zexp Apo-macrocycle  tR 
(min) 
m/zexp clogPa clogPb 
[Fe(PP)2-MC]+ 1a 21.0 482.2 (PP)2-MC 1b 27.6 429.1 -2.84 0.64 
[Fe(PPNO)2-MC]+ 2a 20.9 486.2 (PPNO)2-MC 2b 21.4 433.4 -5.93 -0.71 
[Fe(PPCO)2-MC]+ 3a 25.8 486.2 (PPCO)2-MC 3b 29.7 433.3 -5.12 -1.48 
[Fe(PPNOCO)2-MC]+ 4a 21.4 490.2 (PPNOCO)2-MC 4b 17.9 437.2 -8.21 -3.61 
[Fe(PPCS)2-MC]+ 5a 30.4 518.2 (PPCS)2-MC 5b 30.2 465.2 -3.47 -0.40 
[Fe(PPNOCS)2-MC]+ 6a 22.4 522.1 (PPNOCS)2-MC 6b 22.9 469.3 -6.56 -2.53 
a Calculated using ACD/ChemSketch 2017.2.1. b Calculated using Molinspiration 
(https://www.molinspiration.com/cgi-bin/properties) 
 
Signals in the LC were detected for each of 1a–6a (Figure 1, upper row). Aside from 
the well-resolved and narrow signal for 5a, these signals were broad (3a) and commonly 
contained a low-intensity shoulder (1a, 2a, 4a, 6a), which could be due to the presence of a 
distribution of Fe(III)-macrocycle conformers that were partially resolved by the LC 
conditions. The experimental MS isotope pattern at the peak maxima (Figure 1, middle row) 
for 1a–6a correlated well with calculated isotope patterns (Figure 1, lower row). The LC 
signals were ascribed to the dimeric hydroxamic acid Fe(III)-macrocycles, as determined 
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from EIC measurements, which correlated strongly with the SIM traces (Fig. S7, top and 
middle rows). EIC signals that corresponded with the [M+H]+ adducts of the trimeric Fe(III)-
macrocycles were discernible only at baseline levels (Fig. S7, lower row), which showed the 
MTS reaction stoichiometry favoured the formation of the dimeric macrocycles. The signal 
for 5a at m/z 518.2 was present with a signal at m/z 501.1 ascribable to co-eluting diphenyl 
hydrogen phosphate [2M+H]+ as a product of DPPA-mediated peptide coupling.44,45 
 
 
Figure 1. Complexes between Fe(III) and dimeric hydroxamic acid macrocycles (1a–6a) 
produced using MTS, as characterised using LC-MS (SIM detection) (upper row, left to 
right), with experimental (middle row) or calculated (lower row) isotope patterns shown in 
each corresponding column. 
 
Production of apo-dimeric hydroxamic acid macrocycles 
The Fe(III) template was removed from 1a–6a using diethylenetriaminepentaacetic acid 
(DTPA) as a chelator proven effective for this purpose.29 The MTS reaction solutions 
containing 1a–6a were each treated with excess DTPA to compete for the Fe(III) template 
and liberate the corresponding apo-macrocycle 1b–6b. LC signals for 1b–4b and 6b appeared 
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as sharp, single peaks (Figure 2, upper row), with experimental MS isotope patterns (Figure 
2, middle row) in agreement with calculated data (Figure 2, lower row). The major MS signal 
correlated with the [M+H]+ adduct of the neutral apo-macrocycle, with lower intensity 
signals present for sodium and potassium adducts. The solutions were analysed for the 
presence of Fe(III)-free trimeric macrocycles, with minor peaks detected at <1% area of the 
dimeric analogues (Fig. S8). In the case of 5b, two well resolved signals were observed at tR 
30.2 min (peak 1) and tR 38.5 min (peak 2). The EIC data (Fig. S8, middle row) showed that 
each peak was ascribable to a species with SIM 465. These two peaks were separated using 
semi-preparative HPLC for further analysis (Fig. S9). As expected, MS analysis of the 
separate solutions gave isotope patterns at 465.2 (peak 1) or 465.3 (peak 2). It was likely that 
one of these peaks was ascribable to 5b and that the second peak was due to an artefact of the 
reaction and/or side-product. The authenticity of 5b was confirmed upon adding an aliquot of 
Fe(III) to each isolated solution. In the case of peak 1, the holo-macrocycle 5a was re-
constituted (Fig. S9e, g), while no LC signal was observed for 5a from a solution of Fe(III) 
and peak 2 (Fig. S9f). This identified peak 1 as apo-macrocycle 5b and peak 2 as a species 
that had an m/z value coincident with 5b but that was not relevant as a target. The species in 





Figure 2. Dimeric hydroxamic acid apo-macrocycles (1b–6b) detected upon removing 
Fe(III) from 1a–6a, as characterised using LC-MS (SIM detection) (upper row, left to right), 
with experimental (middle row) or calculated (lower row) isotope patterns shown in each 
corresponding column. 
 
 A more accurate comparison of LC retention times for 1b–6b was obtained from 
acquiring the LC trace from a mixture of the apo-macrocycles that had been isolated as 
individual fractions from the LC, with the authenticity of each compound shown using 
HRMS (Fig. S10–S15). The LC trace from this composite solution (Figure 3a) showed a 
positive correlation between the cLogP values and the LC retention time for 1b–6b (r = 0.82 
or 0.62 for ACD ChemSketch or Molinspiration cLogP calculators, respectively) (Figure 3b). 
The data points for 2b and 3b were the most significant outliers from the line of best fit. 
Despite the presence of two ether oxygen atoms, which would be expected to increase 
polarity, 3b eluted in a less polar window than the methylene isostere 1b. Apo-macrocycle 
4b, which contained four ether oxygens, eluted in the most polar region of the LC. Apo-
macrocycle 2b eluted in the second most polar region of the LC and in a significantly 
different window to the isomer 3b. This showed the position of the ether oxygen atom in the 
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diamine-containing region (2b) or the dicarboxylic acid-containing region (3b) had a 
significant effect on the solvation properties, based on the surrogate measure of LC retention 
time. 
 The retention time of the holo-macrocycles 1a–6a (Figure 2) and the corresponding 
apo-macrocycles 1b–6b (Figure 1) were examined (Figure 3c). In the case of the systems 2, 5 
and 6, the retention time of the holo- and apo-macrocycles were similar. In the case of 
systems 1 and 3, the removal of Fe(III) produced a free ligand that eluted in a less polar LC 
window than the Fe(III) complex. System 4 showed the opposite trend, with the apo-
macrocycle eluting in more polar LC window than the Fe(III) complex. These qualitative 
observations demonstrate the effects of the type of group present in a macrocycle (methylene, 
oxygen, sulfur), its position, and the presence or absence of Fe(III) on the LC elution 
behaviour as a proxy of solvation properties. This demonstrates the potential of introducing 
elements of structural diversity into a siderophore macrocycle to moderate its properties.46,47 
 
 
Figure 3. LC from a mixture of isolated solutions of 1b–6b with detection using multiple 
SIM values (A), a plot of cLogP values of 1b–6b versus retention time (B) using ACD 
ChemSketch (black) or Molinspiration (grey) calculators, and a plot of the retention time of 
the apo-macrocycles 1b–6b (open circles) and the corresponding holo-macrocycles 1a–6a 
(closed circles) (C, using data from Figure 1 and Figure 2). 
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Density functional theory (DFT) calculations of 1b–6b 
Density functional theory (DFT) calculations were used to calculate selected molecular 
properties and estimate the solvation energetics of 1b–6b (Table 2). Of most interest was to 
provide a rationale for the significant difference in RP-HPLC retention times observed by 
experiment for the constitutional isomers 2b and 3b. Although no symmetry constraints were 
imposed, all of the structures of 1b–6b converged with pseudo-C2 symmetry with the rotation 




Figure 4. Three projections of the optimised structures of 1b–6b calculated using the 
B3LYP/DGDZVP/PCM methodology. 
 
 Analysis of the calculated molecular properties for 1b–6b indicated 3b as an outlier, 
particularly in terms of the calculated dipole moment. The calculated dipole moments (µ) of 
1b, 2b and 4b–6b ranged between 13.0 to 17.7 D (Table 2), with the value for 3b (µ = 3.7 D) 
showing a reduced polarity. Origins of this difference lie in the steric and electronic 
constraints imposed by inserting the ether group between the two carbonyl groups. In this 
position, the ether oxygen atom forces the amide groups to twist and point away from the 
macrocyclic cavity (essentially orthogonal to the pseudo-C2 axis). In contrast to the other 
compounds in the series, this twist in 3b, reduces the polarity and the dipole moment. The 
effect can be seen in the electrostatic potential maps of 2b and 3b (Figure 5). No such 
difference was observed in the calculated properties or optimised structure of 5b, which 
contains a thioether group in place of the ether group of 3b (Figure S16). The larger sulfur 
atom in 5b allows for increased conformational flexibility in the ring. Placing the ether group 
in the centre of the diaminopentane-derived region in 2b did not induce the same 
conformational restrictions, with 2b retaining a high polarity. No discernible trend was 
observed in the calculated solvation energies (Table 2). 
 



































(PP)2-MC 1b 14.4 349 604 494 13103 -41.7 -41.7 -41.1 
(PPNO)2-MC 2b 17.7 326 587 495 13070 -40.8 -36.6 -40.5 
(PPCO)2-MC 3b 3.7 329 582 482 13040 -83.1 -83.7 -83.0 
(PPNOCO)2-MC 4b 15.2 305 561 465 12566 -62.1 -64.6 -61.1 
(PPCS)2-MC 5b 13.0 374 613 496 14509 -87.1 -87.5 -86.9 
(PPNOCS)2-MC 6b 15.8 352 595 497 14340 -58.2 -59.8 -57.0 
 
 
Figure 5. DFT optimised structures of 2b and 3b, and the calculated electrostatic potential 
maps (ESP; with charge in the range -0.115e to 0.115e) showing projections from the top 
face (centre) as viewed down the pseudo-C2 rotation axis, and the opposing bottom face 
(right). ESPs are projected onto the total electron density isosurface (at the 99.9% cut-off). 
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Structures were optimised using the B3LYP/DGDZVP methodology and calculations 
included solvation effects in water using a polarisable continuum model (PCM). 
 
Conclusion 
This work has reported a new synthesis for endo-HXA monomers that furnishes these ligands 
in higher yields (2–5 times greater) and in less time (3–4 times less) than previous methods. 
The use of the nosyl protecting group adds value to the synthesis through its orthogonality to 
other N-protecting groups and its removal under mild conditions. The amino-alcohol reagent 
used in the first step allows an expansion in structural diversity in endo-HXA monomers, due 
to the ready availability of different analogues. The endo-HXA ligands 1–6 were used in 
successful MTS reactions in a 1:2 Fe(III):ligand stoichiometry to produce the corresponding 
Fe(III)-loaded dimeric hydroxamic acid macrocycles 1a–6a, which following treatment with 
DTPA, gave the apo-macrocycles 1b–6b. Apo-macrocycles 1b–6b gave different retention 
times on an RP-HPLC column, which reflected different solvation properties ascribable to the 
presence and position of methylene groups and ether and/or thioether atoms. The optimised 
structures and solvation properties of the ether-containing isomers 2b and 3b were examined 
by DFT calculations. Results confirmed that 3b was anomalous in the series and that an ether 
group positioned between the carbonyl centres imposed steric and electronic constraints that 
invoked a twist in the macrocycle which reduced the molecular polarity. Improved access to 
endo-HXA monomers could support MTS as a more robust method for generating metal-
tailored macrocycles and other syntheses requiring these types of ligands. The increased 
yields of endo-HXA ligands will better support our current efforts in obtaining X-ray crystal 




All reactions were performed under an inert nitrogen atmosphere. The progress of reactions 
was monitored by thin layer chromatography (TLC), with plates visualized using UV light at 
254 nm or by staining with ninhydrin, vanillin or FeCl3. 1H and 13C nuclear magnetic 
resonance (NMR) spectroscopy was performed on a Bruker 600 MHz AVIIII with a TCI 
cryoprobe at 25 °C operating with Topspin 3.5 NMR software. Samples were made to a 
concentration of 10 mg mL–1 in CDCl3 (Sigma-Aldrich, 99.8%), CD3OD (Cambridge Isotope 
Laboratory, 99.8%) or DMSO-d6 (Cambridge Isotope Laboratory, 99.9%). Chemical shifts 
are reported in ppm relative to the residual solvent peaks (CDCl3: δH 7.27 ppm, δC 77.23 
ppm; CD3OD: δH 3.31 ppm, δC 49.00 ppm; DMSO-d6: δH 2.50 ppm, δC 39.52 ppm). Signal 
multiplicities are labelled as: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintet) or m 
(multiplet). Coupling constants are designated J (Hz). High-resolution mass spectrometry 
(HRMS) was conducted on a Bruker solariX 2XR 7T Fourier Transform Ion Cyclotron Mass 




1-Amino-5-pentanol (95%), 2-(2-aminoethoxy)ethanol (98%), 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU, 98%), dichloromethane (≥ 99.8%), 1,4-dioxane-2,6-dione (common name: 
diglycolic anhydride, 95%), diisopropyl azodicarboxylate (DIAD, 99%), diphenylphosphoryl 
azide (DPPA, 97%), di-tert-butyl dicarbonate (99%), glutaric anhydride (95%), iron(III) 
acetylacetonate (97%), triethylamine (≥ 99%), methanol (99.8%), 2-mercaptoethanol (≥ 
99%), N,N-dimethylformamide (99.8%), succinic anhydride (≥ 99%), tetrahydrofuran (≥ 
99%), tert-butanol (≥ 99.5%) and trifluoroacetic acid (99%) were purchased from Sigma-
Aldrich (Castle Hill, Australia). Hexane and ethyl acetate were purchased from Thermofisher 
Scientific (Sydney, Australia). 1,4-Oxathiane-2,6-dione (thiodiacetic anhydride) (98%) was 
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purchased from Fluorochem (Hadfield, United Kingdom). All solvents were anhydrous 
unless stated otherwise. All chemicals were used as received. Milli-Q water was used for all 





Flash chromatography was performed on a Grace Reveleris X2 Auto Flash system using 
hexane and ethyl acetate as solvents, unless specified otherwise. The cartridges sizes and 
flow rates were varied depending on the scale of the reaction: 0.1–1 g-scale reaction 
(cartridge = 12 g, flow rate = 30 mL min-1), 1–8 g-scale reaction (cartridge: 40 g, flow rate = 
40 mL min-1). Methods were developed using the Reveleris auto-gradient feature based on Rf 
values from TLC experiments. Crude compounds were dissolved in a minimum amount of 
ethyl acetate and injected onto the column via the injection port. 
 
Reverse-phase liquid chromatography-mass spectrometry 
Reverse-phase liquid chromatography-mass spectrometry (RP LC-MS) was employed using 
an Agilent Technologies HPLC system (Santa Clara, CA) consisting of an autoinjector (100 
µL loop), an Agilent 1260 Infinity degasser, a quaternary pump and an Agilent 6120 Series 
Quadrupole electrospray ionization (ESI) mass spectrometer. An Agilent C18 column 
reverse-phased prepacked column (4.6 × 150 mm i.d., particle size 5 µm) was used for all 
experiments. Agilent OpenLAB Chromatography Data System (CDS) ChemStation Edition 
was used to process mass chromatograms in each of the scan and the selected ion monitoring 
(SIM) or extraction ion chromatogram (EIC) detection modes. Samples were made to a 
concentration of 1 mg mL-1 in MeOH or for MTS samples in 1:1 DMF:H2O. The following 
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instrumental conditions were used: flow rate 0.5 mL min-1, injection volume 5 µL, spray 
voltage 4 kV, capillary voltage 3 kV, capillary temperature 250 °C, tube lens offset 10 V. 
Mobile phases were prepared by mixing acetonitrile (ACN):formic acid (99.9:0.1, mobile 
phase B) and H2O:formic acid (99.9:0.1, mobile phase A). Method A: 0–100% ACN:H2O 
gradient over 45 min. Method B: 0–28% ACN:H2O gradient over 40 min. 
 
H-Cube 
Hydrogenation was performed on an H-cube Mini Plus with a micro HPLC pump. The 10% 
Pd/C CatCart was from ThalesNano (ID: THS-01111). The mobile phase was prepared by 
mixing tert-butanol:ethyl acetate (9:1). The method used a temperature of 60 °C and a flow 





A methanol solution (1 mL) containing 1 (4.1 mg, 17.6 µmol) was added to a methanol 
solution (1 mL) containing Fe(acac)3 (3.1 mg, 8.8 µmol) to give a 2 mg mL-1 solution with 
respect to 1. The solution was stirred for 2 h and the solvent was removed in vacuo and the 
product was dried under high vacuum overnight. DMF (4 mL) was added to the crude 
mixture followed by the addition of DPPA (29 µL, 35.2 µmol) and Et3N (10.7 µL, 35.2 
µmol). The reaction mixture was stirred for 5 d and aliquots of 100 µL were taken from the 
mixture and diluted with milli-Q water (100 µL) to quench the reaction. Analogous 
procedures were conducted for 2–6. Reaction mixtures were analysed by LC-MS (positive 
ion) using TIC, SIM and EIC detection modes. 
 
23 
Removing Fe(III) from holo-macrocycles 1a–6a 
An aliquot of the reaction mixture (100 µL) was taken and diluted with an equivalent aliquot 
of DTPA (0.2 M) and the mixture was left to incubate overnight. A sample was taken and 
analysed by LC-MS. 
 
Isolation of apo-macrocycles 1b–6b by HPLC 
The MTS solutions treated with DTPA containing 1b–6b were analysed by HRMS and were 
purified by HPLC (Method B). Fractions were collected over the following elution times: 1b 
(26–30 min), 2b (19–23 min), 3b (27–31 min), 4b (15–19 min), 5b (peak 1, 28–32 min; peak 
2, 36–40 min), 6b (20–24 min). The ACN was removed via rotary evaporation and the 
fractions were then lyophilised to dryness. The solid was re-dissolved in 200 µL water and 
the solutions were pooled and analysed by LC-MS and HRMS. 
 
Computational details 
All calculations were conducted using density functional theory (DFT) as implemented in the 
Gaussian16 Revision A.03 suite of ab initio quantum chemistry programs. Normal self-
consistent field (SCF) and geometry convergence criteria were employed throughout and 
structures were optimised without using symmetry constraints. All structures were optimised 
in the gas phase, and in solution phase using a polarisable continuum model (PCM) and the 
B3LYP/DGDZVP methodology. Solvated phase calculations were implemented by using the 
SCRF keyword with default parameters and selecting water as the solvent (dielectric 
constant, e = 78.3553). Harmonic frequency analysis based on analytical second derivative 
was used to characterise optimised structures as local minima. The choice of solvation model 
reflects our standard aqueous phase conditions employed in the potential use and application 
of the macrocyclic chelates described in this work. Optimised structures were analysed by 
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using Chemcraft (version 1.8, build 536b) and GaussView 6.0.16 (Gaussian Inc., 
Wallingford, MA). Electrostatic potentials (calculated in the range -0.115e to +0.115e) were 





O-Benzylhydroxylamine hydrochloride (5.0 g, 31.3 mmol) was dissolved in anhydrous 
pyridine (60 mL), stirred vigorously and cooled to -5 °C. A solution of 2-nitrobenzylsulfonyl 
chloride (7.1 g, 32.0 mmol) in pyridine (20 mL) was added dropwise. The solution was left to 
stir at -5 °C for 30 min then allowed to warm to r.t. and stirred for a further 2 h. H2O (15 mL) 
was added to terminate the reaction and the solvents were removed in vacuo. The residue was 
re-dissolved in EtOAc:H2O (1:1, 400 mL) and partitioned in a separatory funnel. The organic 
layer was washed with 5% HCl, H2O and NaHCO3 (200 mL each). The organic layer was 
concentrated in vacuo to yield the semi-pure product as an orange crystalline solid (6.9 g, 
70%). 1H NMR (600 MHz, CDCl3): δH 8.24–8.26 (m, 1H), 8.12 (s, 1H), 7.78–7.88 (m, 3H), 
7.37 (s, 5H), 5.10 (s, 2H). 13C NMR (150 MHz, CDCl3): δC 149.1, 135.6, 135.3, 132.5, 
130.3, 129.7, 128.5, 124.6, 78.7. LRMS (ESI+): m/z ([M+H]+, 100%): 309.2. The data are 
consistent with literature.41 
 
O-tert-Butyl-N-(2-nitrophenylsulfonyl)hydroxylamine 
O-tert-Butylhydroxylamine hydrochloride (5.06 g, 40.2 mmol) was dissolved in anhydrous 
CHCl3 (80 mL) and the reaction cooled to -5 °C. Et3N (11.7 mL, 84.4 mmol) was added 
dropwise, followed by the dropwise addition of a solution of 2-nitrobenzylsulfonyl chloride 
(8.93, 40.2 mmol) in CHCl3 (50 mL). The reaction was stirred at -5 °C for 2 h, warmed to r.t. 
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and left stirring overnight. The reaction mixture was washed with H2O, 1 M HCl, H2O, 5% 
NaHCO3, H2O and brine (40 mL each). The organic layer was concentrated in vacuo to yield 
the product as a yellow crystalline solid (8.82 g, 80%). 1H NMR (600 MHz, CDCl3): δH 
8.15–8.16 (m, 1H), 7.78–7.86 (m, 3H), 1.26 (s, 9H). 13C NMR (150 MHz, CDCl3): δC 148.5, 
134.5, 133.8, 133.7, 132.7, 125.3, 82.9, 26.7. LRMS (ESI+): m/z ([M+H]+, 100%): 275.1. 
The data are consistent with literature.41 
 
N-Boc-1-amino-5-pentanol (7) 
To a solution of 1-amino-5-pentanol (1.50 g, 14.5 mmol) in CH2Cl2 (120 mL) was added a 
solution of Boc2O (3.16 g, 14.5 mmol) in CH2Cl2 (10 mL). The solution was treated with 
Et3N (2.22 mL, 15.9 mmol) dropwise and the mixture was stirred for 4 h. The reaction was 
concentrated in vacuo and the crude product was purified using auto flash chromatography 
(gradient: 30% EtOAc over 2 min, 30% to 60% over 5 min, 60% over 2 min) to afford the 
product as a yellow oil (90%). 1H NMR (600 MHz, CDCl3): δH 3.67 (t, J = 6.5 Hz, 2H), 3.20 
(d, J = 6.2 Hz, 2H), 1.63 (qn, J = 7.2 Hz, 2H), 1.56 (qn, J = 7.3 Hz, 2H), 1.49 (s, 9H), 1.42–
1.46 (m, 2H); 13C NMR (150 MHz, CDCl3): δC 156.1, 77.1, 62.3, 40.4, 32.2, 29.8 28.4, 22.9. 
LRMS (ESI+): m/z ([M+Na]+, 100%): 226.1. The data are consistent with literature.48 
 
N-Boc-2-(2-aminoethoxy)ethanol (8) 
To a solution of 2-(2-aminoethoxy)ethanol (1.52 g, 14.5 mmol) in CH2Cl2 (120 mL) was 
added a solution of Boc2O (3.16 g, 14.5 mmol) in CH2Cl2 (10 mL). The solution was treated 
with Et3N (2.22 mL, 15.9 mmol) dropwise and the mixture was stirred for 4 h. The reaction 
was concentrated in vacuo and the crude product was purified using auto flash 
chromatography (gradient: 30% EtOAc over 2 min, 30% to 60% over 5 min, 60% over 2 
min), to afford the product as a yellow oil (90%). 1H NMR (600 MHz, CDCl3): δH 5.21 (s, 
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1H), 3.67–3.69 (m, 2H), 3.49–3.53 (m, 4H), 3.26–3.29 (m, 2H), 1.40 (s, 9H). 13C NMR (150 
MHz, CDCl3): δC 156.3, 79.1, 72.2, 70.1, 61.2, 40.23, 28.4. LRMS (ESI+): m/z ([M+Na]+, 
100%): 228.1. The data are consistent with literature.49 
 
N,O-Bis-protected hydroxylamine compounds 13–16 
To a solution of 7 (1.50 g, 7.38 mmol) or 8 (1.51 g, 7.38 mmol) in THF (15 mL) was added 
O-tert-butyl-N-(2-nitrophenylsulfonyl)hydroxylamine (2.03 g, 7.38 mmol) or O-benzyl-N-(2-
nitrophenylsulfonyl)hydroxylamine (2.25 g, 7.38 mmol) and PPh3 (5.80 g, 22.14 mmol). 
After stirring for 15 min, the reaction was cooled to 0 °C and DIAD (4.48 mL, 22.14 mmol) 
was added dropwise. The mixture was stirred for 30 min and then heated to 40 °C and stirred 
for 8 h. The reaction was concentrated in vacuo, diluted with diethyl ether, cooled to 0 °C and 
stirred until a precipitate formed. The mixture was filtered, and the filtrate was concentrated 
in vacuo and purified using auto flash chromatography (gradient: 9% EtOAc over 1 min, 9–
28% over 10 min, 28% over 2 min) to furnish the semi-pure nosyl protected amine compound 
(9–12) as an orange oil. Products 9–12 were not further characterised and were used directly 
in the next step of the synthesis. The product was re-dissolved in DMF (10 mL), treated with 
2-mercaptoethanol (517 µL, 7.38 mmol) and DBU (1.12 mL, 7.38 mmol) and the solution 
was stirred for 3 h. The reaction was concentrated in vacuo, diluted with water and extracted 
with CH2Cl2. The crude mixture was purified using auto flash chromatography (gradient: 
10% EtOAc over 2 min, 10–25% over 4 min, 25% over 5 min), to yield 13–16 as a yellow oil 
(75% over two steps). 
 
tert-Butyl (5-(tert-butoxyamino)pentyl)carbamate (13). 1H NMR (600 MHz, CDCl3): δH 
3.22 (d, J = 7.2 Hz, 2H), 2.94 (t, J = 7.1 Hz, 2H), 1.58 (qn, J = 6.2 Hz, 4H), 1.54 (s, 9H), 
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1.43–1.47 (m, 2H), 1.28 (s, 9H); 13C NMR (150 MHz, CDCl3): δC 155.9, 79.0, 77.2, 52.8, 
40.5, 30.0, 28.4, 27.0, 26.8, 24.5. LRMS (ESI+): m/z ([M+H]+, 100%): 275.3. 
 
tert-Butyl (2-(2-(tert-butoxyamino)ethoxy)ethyl)carbamate (14). 1H NMR (600 MHz, 
CDCl3): δH 3.53 (t, J = 5.1 Hz, 4H), 3.48 (d, J = 4.6 Hz, 2H), 3.28 (s, 2H), 2.97 (t, J = 5.1, 
2H), 1.55 (s, 9H), 1.29 (s, 9H). 13C NMR (150 MHz, CDCl3): δC 156.0, 76.8, 69.8, 67.1, 
60.4, 52.5, 40.3, 28.4, 26.7. LRMS (ESI+): m/z ([M+H]+, 100%): 277.2. 
 
tert-Butyl (5-((benzyloxy)amino)pentyl)carbamate (15). 1H NMR (600 MHz, CDCl3): δH 
7.26-7.32 (m, 5H), 4.67 (s, 2H), 3.07 (s, 2H), 2.89 (t, J = 7.1 Hz, 2H), 1.49 (qn, J = 7.5 Hz, 
2H), 1.42-1.45 (m, 2H), 1.41 (s, 9H), 1.30 (qn, J = 7.7, 2H). 13C NMR (150 MHz, CDCl3): δC 
171.2, 137.9, 128.4, 128.3, 127.7, 77.4, 76.1, 51.9, 40.4, 29.9, 28.4, 27.0, 24.3. LRMS 
(ESI+): m/z ([M+H]+, 100%): 309.2. 
 
tert-Butyl (2-(2-((benzyloxy)amino)ethoxy)ethyl)carbamate (16). 1H NMR (600 MHz, 
CDCl3): δH 7.26-7.33 (m, 5H), 4.69 (s, 2H), 3.58 (t, J = 5.1 Hz, 2H), 3.55 (t, J = 4.8 Hz, 2H), 
3.28 (d, J = 4.6 Hz, 2H), 3.06 (t, J = 5.1 Hz, 2H), 1.42 (s, 9H). 13C NMR (150 MHz, CDCl3): 
δC 156.0, 137.9, 128.4, 128.3, 127.8, 79.2, 76.0, 70.0, 67.2, 51.5, 40.4, 28.4. LRMS (ESI+): 
m/z ([M+H]+, 100%): 311.2. 
 
Glutarylated N,O-bis-protected hydroxylamine compounds 17–22 
To a solution of 13 (401 mg, 1.46 mmol), 14 (404 mg, 1.46 mmol), 15 (450 mg, 1.46 mmol) 
or 16 (453 mg, 1.46 mmol) in CH2Cl2 (10 mL) was added either glutaric anhydride (167 mg, 
1.46 mmol), 1,4-dioxane-2,6-dione (169 mg, 1.46 mmol) or 1,4-oxathiane-2,6-dione (193 
mg, 1.46 mmol). The mixture was stirred for 3 h, concentrated in vacuo and purified using 
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auto flash chromatography (gradient: 29% EtOAc over 2 min, 29–61% over 7 min, 61% over 
4 min) to afford the product as a white solid (17, 21–22) or a clear oil (18–20) (85%). 
 
5-(tert-Butoxy(5-((tert-butoxycarbonyl)amino)pentyl)amino)-5-oxopentanoic acid (17). 
1H NMR (600 MHz, CDCl3): δH 2.41 (qn, J = 7.4 Hz, 4H), 1.93 (qn, J = 7.0 Hz, 4H), 1.60 (t, 
J = 7.1 Hz, 2H), 1.46-1.47 (m, 2H), 1.41 (s, 9H), 1.27 (s, 9H), 1.23 (t, J = 7.1 Hz, 4H). 13C 
NMR (150 MHz, CDCl3): δC 178.0, 171.3, 82.7, 79.2, 60.4, 40.4, 33.2, 32.9, 29.6, 28.4, 23.9, 
21.0, 19.8, 19.6, 14.2. LRMS (ESI+): m/z ([M+Na]+, 100%): 411.3. 
 
11-(tert-butoxy)-2,2-dimethyl-4,12-dioxo-3,8-dioxa-5,11-diazahexadecan-16-oic acid 
(18). 1H NMR (600 MHz, CDCl3): δH 3.75 (s, 2H), 3.56 (s, 4H), 3.34 (s, 2H), 2.50 (t, J = 7.0 
Hz, 2H), 2.03 (t, J = 7.0 Hz, 2H), 1.53 (s, 9H), 1.39 (s, 9H). 13C NMR (150 MHz, CDCl3): δC 
177.9, 156.2, 79.3, 69.7, 66.2, 50.5, 40.3, 33.1, 32.1, 28.4, 27.6, 19.9. LRMS (ESI+): m/z 
([M+Na]+, 100%): 413.2. 
 
11-(Benzyloxy)-2,2-dimethyl-4,12-dioxo-3,14-dioxa-5,11-diazahexadecan-16-oic acid 
(19). 1H NMR (600 MHz, CDCl3): δH 7.33-7.42 (m, 5H), 4.80 (s, 2H), 4.20 (s, 2H), 4.01 (s, 
2H), 3.71 (s, 2H), 3.10 (s, 2H), 1.68 (qn, , J = 7.3 Hz, 2H),  1.50 (qn, , J = 7.4 Hz, 2H), 1.43 
(s, 9H), 1.32 (s, 2H). 13C NMR (150 MHz, CDCl3): δC 172.5, 165.6, 133.7, 129.7, 129.6, 
129.5, 129.0, 128.9, 76.2, 45.4, 40.3, 29.6, 28.4, 26.4, 26.2, 24.7, 22.8. LRMS (ESI+): m/z 
([M+Na]+, 100%): 447.2. 
 
11-(Benzyloxy)-2,2-dimethyl-4,12-dioxo-3,8,14-trioxa-5,11-diazahexadecan-16-oic acid 
(20). 1H NMR (600 MHz, CDCl3): δH 7.39- 7.45 (m, 5H), 4.91 (s, 2H), 4.31 (s, 2H), 4.20 (s, 
2H), 4.10 (s, 2H), 3.66 (t, J = 5.1 Hz, 2H), 3.49 (t, J = 5.6 Hz, 2H), 3.20 (t, J = 5.5 Hz, 2H), 
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1.40 (s, 9H). 13C NMR (150 MHz, CDCl3): δC 172.2, 157.0, 134.5, 129.5, 128.8, 128.4, 78.7, 




(21). 1H NMR (600 MHz, MeOD4): δH 3.82 (s, 2H), 3.52 (s, 2H), 3.13 (t, J = 7.0 Hz, 2H), 
1.56-1.59 (m, 2H), 1.53 (s, 9H), 1.44 (s, 9H), 1.37-1.41 (m, 4H). 13C NMR (150 MHz, 
MeOD4): δC 172.2, 83.5, 77.9, 77.7, 77.5, 51.7, 48.8, 33.4, 33.3, 33.1, 32.9, 29.2, 27.0, 24.6. 
LRMS (ESI+): m/z ([M+Na]+, 100%): 429.2. 
 
11-(tert-Butoxy)-2,2-dimethyl-4,12-dioxo-3,8-dioxa-14-thia-5,11-diazahexadecan-16-oic 
acid (22). 1H NMR (600 MHz, CDCl3): δH 3.73 (s, 4H), 3.56 (s, 2H), 3.38 (s, 2H) 3.32 (s, 
2H), 1.50 (s, 9H), 1.39 (s, 9H). 13C NMR (150 MHz, CDCl3): δC 173.2, 156.5, 89.9, 79.7, 
69.8, 66.0, 50.2, 49.6, 40.3, 33.9, 33.7, 28.3, 27.6. LRMS (ESI+): m/z ([M+Na]+, 100%): 
431.2. 
 
endo-Hydroxamic acid amino carboxylic acid (endo-HXA) monomers 1–6 
A solution of 17 (427 mg, 1.1 mmol), 18 (429 mg, 1.1 mmol), 21 (447 mg, 1.1 mmol) or 22 
(449 mg, 1.1 mmol) was prepared in CH2Cl2:TFA (1:9, 5 mL) and the solution was stirred for 
4 h. The mixture was concentrated, re-dissolved in toluene and concentrated in vacuo. Water 
was added and the product was lyophilised yielding an orange gum. The corresponding endo-
HXA ligand 1, 2, 5 or 6 was left as a TFA salt until further reaction was required (95%). A 
solution of 19 (467 mg, 1.1 mmol) or 20 (469 mg, 1.1 mmol) was prepared in tert-
butanol:ethyl acetate (9:1, 18 mL) at a concentration of 50 mM and subject to hydrogenation 
using a H-cube Mini Plus. The collected solution was concentrated in vacuo and the 
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compound was re-dissolved in CH2Cl2:TFA (5 mL, 9:1) and reacted for 2 h. The mixture was 
concentrated and re-dissolved in toluene and concentrated in vacuo. Water was added and the 
solution was lyophilised to yield an orange gum. The corresponding endo-HXA ligand 3 or 4 
was left as a TFA salt until further reaction was required (95%). 
 
5-[(5-Aminopentyl)(hydroxy)amino]-5-oxopentanoic acid (PPH) (1). 1H NMR (600 MHz, 
MeOD4): δH 3.63 (t, J = 6.9 Hz, 2H, H-9), 2.92 (t, J = 7.2 Hz, 2H, H-6), 2.55 (t, J = 6.6 Hz, 
2H, H-2), 2.35 (t, J = 7.2 Hz, 2H, H-11), 1.86-1.90 (qn, J = 7.0 Hz 2H, H-10), 1.68 (t, J = 7.0 
Hz, 4H, H-3,5), 1.38-1.40 (m, 2H, H-4). 13C NMR (150 MHz, MeOD4): δC 175.4, 173.9, 
39.2, 32.5, 30.9, 26.5, 25.7, 22.9, 19.9, 19.8. LRMS (ESI+): m/z ([M+H]+, 100%): 233.1. 
HRMS m/z: [M+H]+ calcd for C10H21N2O4: 233.14958; found: 233.14954. 
 
5-((2-(2-Aminoethoxy)ethyl)(hydroxy)amino)-5-oxopentanoic acid (PPHNO) (2). 1H 
NMR (600 MHz, DMSO-d6): δH 7.81 (bs, 2H, NH3·TFA, H-1) 3.69 (t, J = 5.9 Hz, 2H, H-6), 
3.59 (t, J = 5.9 Hz, H-3) 3.58 (m, J = 5.2 Hz, H-5), 2.95 (q, J = 5.1 Hz, 2H, H-2),  2.40 (t, J = 
7.2 Hz, 2H, H-11), 2.24 (t, J = 7.4, 2H, H-9), 1.70 (qn, J = 7.3 Hz, 2H, H-10). 13C NMR (150 
MHz, DMSO-d6): δC 174.3 (C-8), 172.9 (C-12), 66.4 (C-3, 5), 46.8 (C-6), 38.6 (C-2), 33.0 
(C-9), 30.9 (C-11), 20.0 (C-10). LRMS (ESI+): m/z ([M+H]+, 100%): 235.1. HRMS: m/z: 
[M+H]+  calcd. for C9H19N2O5: 235.12885; found: 235.12867. 
 
2-(2-((5-Aminopentyl)(hydroxy)amino)-2-oxoethoxy)acetic acid (PPHCO) (3). 1H NMR 
(600 MHz, DMSO-d6): δH 7.75 (bs, 2H, NH3·TFA, H-1), 4.32 (s, 2H, H-9), 4.10 (s, 2H, H-
11), 3.47 (t, J = 6.8 Hz, 2H, H-6), 2.73-2.78 (m, 2H, H-2), 1.51-1.56 (m, 4H, H-3,5), 1.27 (qt, 
J = 7.4 Hz, 2H, H-4).  13C NMR (150 MHz, DMSO-d6): δC 171.4 (C-8), 169.3 (C-12), 67.6 
(C-9), 67.2 (C-11), 46.9 (C-6), 38.7 (C-2), 26.7 (C-3, 5), 25.6 (C-4). LRMS: (ESI+): m/z 
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([M+H]+, 100%): 235.1. HRMS: m/z: [M+H]+  calcd. for C9H19N2O5: 235.12885; found: 
235.12882. 
 
2-(2-((2-(2-Aminoethoxy)ethyl)(hydroxy)amino)-2-oxoethoxy)acetic acid (PPHNOCO) 
(4). 1H NMR (600 MHz, DMSO-d6): δH 7.82 (bs, 2H, NH3·TFA, H-1), 4.08 (d, J = 6.4 Hz, 4 
H, H-9,11), 3.66 (t, J = 5.4 Hz, 2H, H-6), 3.59 (t, J = 5.8 Hz, 2H, H-5), 3.58 (t, J = 5.6 Hz, 
2H, H-3) 2.95-2.96 (m, 2H, H-2). 13C NMR (150 MHz, DMSO-d6): δC 171.2 (C-8), 169.9 
(C-12), 67.5 (C-9), 67.2 (C-11), 66.3 (C-3), 66.0 (C-5), 46.9 (C-6), 38.6 (C-2). LRMS 
(ESI+): m/z ([M+H]+, 100%): 237.1. HRMS m/z: [M+H]+  calcd. for C8H17N2O6: 237.10811; 
found: 237.10803. 
 
2-((2-((5-Aminopentyl)(hydroxy)amino)-2-oxoethyl)thio)acetic acid (PPHCS) (5). 1H 
NMR (600 MHz, DMSO-d6): δH 7.69 (bs, 2H, NH3·TFA, H-1), 3.54 (s, 2H, H-9), 3.49 (t, J = 
6.7 Hz, 2H, H-6), 3.34 (s, 2H, H-11) (peak co-incident with water peak; analysed by HSQC) 
2.75-2.76 (m, 2H, H-2), 1.53 (t, J = 7.1 Hz, 4H, H-3,5), 1.27 (t, J = 7.1 Hz, 2H, H-4). 13C 
NMR (150 MHz, DMSO-d6): δC 170.9 (C-8), 168.7 (C-12), 47.0 (C-6), 38.7 (C-2), 33.4 (C-
11), 32.6 (C-9), 26.6 (C3,5), 25.6 (C-4). LRMS (ESI+): m/z ([M+H]+, 100%): 251.1. HRMS 
m/z: [M+H]+  calcd. for C9H19N2O4S: 251.10600; found: 251.10565. 
 
2-((2-((2-(2-Aminoethoxy)ethyl)(hydroxy)amino)-2-oxoethyl)thio)acetic acid (PPHNOCS) 
(6). 1H NMR (600 MHz, DMSO-d6): δH 7.76 (bs, 2H, NH3·TFA, H-1), 3.70 (t, J = 5.6 Hz, 
2H, H-6), 3.56-3.62 (m, 8H, H-3, 5, 9, 11), 2.96 (s, 2H, H-2). 13C NMR (150 MHz, DMSO-
d6): δC 170.9 (C-8), 169.3 (C-12), 66.3 (C-3, 5), 46.9 (C-6), 38.6 (C-2), 32.6 (C-9, 11). 
LRMS (ESI+): m/z ([M+H]+, 100%): 253.1. HRMS: m/z: [M+H]+  calcd. for C8H17N2O5S: 
253.08527; found: 253.08501. 
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Electronic supplementary information (ESI). Additional data for 1–6 (NMR spectroscopy, 
HRMS). See DOI: 
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